Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Perceptive Advisors and Oncomed Pharmaceuticals Inc (OMED)

Oncomed Pharmaceuticals Inc (NASDAQ:OMED): Joseph Edelman’s Perceptive Advisors filed an amended 13D.

You can check out Perceptive Advisors’ latest holdings and filings here.

Please follow Perceptive Advisors (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Perceptive Advisors or update its stock holdings.

Joseph Edelman
Joseph Edelman
Perceptive Advisors

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Perceptive Advisors 0 2,470,897 0 2,470,897 2,470,897 6.5%
Joseph Edelman 0 2,470,897 0 2,470,897 2,470,897 6.5%
Perceptive Life Sciences Master Fund, Ltd 0 2,470,897 0 2,470,897 2,470,897 6.5%
Joseph Edelman
Joseph Edelman
Perceptive Advisors

Page 1 of 8 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

OncoMed
Pharmaceuticals, Inc.

(Name of Issuer)

common stock, par value $0.001 per share

(Title of Class of Securities)

68234X 10 2

(CUSIP
Number)

November 6, 2017

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)


Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 2 of 8 – SEC Filing


  1

NAMES OF
REPORTING PERSONS

Perceptive Advisors LLC

  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP (SEE INSTRUCTIONS)

(a)  ☐        (b)  ☐

  3

SEC USE ONLY

  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,470,897

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,470,897

  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,470,897

10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW 9

6.5%

12

TYPE OF REPORTING PERSON (SEE
INSTRUCTIONS)

IA

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 3 of 8 – SEC Filing


  1

NAMES OF
REPORTING PERSONS

Joseph Edelman

  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP (SEE INSTRUCTIONS)

(a)  ☐        (b)  ☐

  3

SEC USE ONLY

  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,470,897

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,470,897

  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,470,897

10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW 9

6.5%

12

TYPE OF REPORTING PERSON (SEE
INSTRUCTIONS)

IN

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 4 of 8 – SEC Filing


  1

NAMES OF
REPORTING PERSONS

Perceptive Life Sciences Master Fund, Ltd.

  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP (SEE INSTRUCTIONS)

(a)  ☐        (b)  ☐

  3

SEC USE ONLY

  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman Islands

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,470,897

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,470,897

  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,470,897

10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW 9

6.5%

12

TYPE OF REPORTING PERSON (SEE
INSTRUCTIONS)

CO

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 5 of 8 – SEC Filing


Item 1(a). Name of Issuer:

OncoMed Pharmaceuticals, Inc. (the Issuer)

Item 1(b). Address of Issuers Principal Executive Offices:

800 Chesapeake Drive

Redwood City, California 94063

Item 2(a). Names of Persons Filing:

The names of the persons filing this report
(collectively, the Reporting Persons) are:

Perceptive Advisors LLC (Perceptive Advisors)

Joseph Edelman (Mr. Edelman)

Perceptive Life Sciences Master Fund, Ltd. (the Master Fund)

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the
principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor

New York, NY 10003

Item 2(c). Citizenship:

Perceptive Advisors is a Delaware limited liability company

Mr. Edelman is a United States citizen

The Master Fund is a Cayman Islands corporation

Item 2(d). Title of Class of Securities:

common stock, par value $0.001
per share (Common Stock)

Item 2(e). CUSIP Number:

68234X 10 2

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is
a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting
Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 37,856,476 outstanding shares of Common Stock, as reported in the Issuers Form 10-Q filed on November 2, 2017.

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 6 of 8 – SEC Filing


The Master Fund directly holds 2,470,897 shares of Common Stock. Perceptive Advisors serves as
the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities
directly held by the Master Fund.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed
to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the SubsidiaryWhich Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 7 of 8 – SEC Filing


SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this
statement is true, complete and correct.

Date: December 6, 2017

PERCEPTIVE ADVISORS LLC

By:

/s/ Joseph Edelman

Name: Joseph Edelman
Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC
By:

/s/ Joseph Edelman

Name: Joseph Edelman
Title: Managing Member

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 8 of 8 – SEC Filing


EXHIBIT 1

AGREEMENT

The persons below hereby agree that
the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: December 6, 2017

PERCEPTIVE ADVISORS LLC

By:

/s/ Joseph Edelman

Name: Joseph Edelman
Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC
By:

/s/ Joseph Edelman

Name: Joseph Edelman
Title: Managing Member
Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!